Symbols / CDNA $20.63 -0.48% CareDx, Inc.
CDNA Chart
About
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Fundamentals
Scroll to Statements| Market Cap | 1.06B | Enterprise Value | 905.58M | Income | -21.35M | Sales | 379.80M | Book/sh | 5.95 | Cash/sh | 3.46 |
| Dividend Yield | — | Payout | 0.00% | Employees | 761 | IPO | — | P/E | — | Forward P/E | 18.89 |
| PEG | — | P/S | 2.79 | P/B | 3.47 | P/C | — | EV/EBITDA | -116.17 | EV/Sales | 2.38 |
| Quick Ratio | 2.45 | Current Ratio | 2.86 | Debt/Eq | 8.64 | LT Debt/Eq | — | EPS (ttm) | -0.40 | EPS next Y | 1.09 |
| EPS Growth | — | Revenue Growth | 25.20% | Earnings | 2026-04-28 | ROA | -3.15% | ROE | -6.27% | ROIC | — |
| Gross Margin | 67.55% | Oper. Margin | -3.49% | Profit Margin | -5.62% | Shs Outstand | 51.22M | Shs Float | 49.62M | Short Float | 12.84% |
| Short Ratio | 10.41 | Short Interest | — | 52W High | 23.24 | 52W Low | 10.96 | Beta | 2.54 | Avg Volume | 679.09K |
| Volume | 477.43K | Target Price | $24.80 | Recom | Buy | Prev Close | $20.73 | Price | $20.63 | Change | -0.48% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | BTIG | Buy → Buy | $26 |
| 2026-02-25 | main | Wells Fargo | Equal-Weight → Equal-Weight | $21 |
| 2025-12-15 | main | Wells Fargo | Equal-Weight → Equal-Weight | $18 |
| 2025-11-06 | main | BTIG | Buy → Buy | $25 |
| 2025-09-23 | reit | BTIG | Buy → Buy | $22 |
| 2025-09-12 | reit | BTIG | Buy → Buy | $22 |
| 2025-08-26 | init | William Blair | — → Market Perform | — |
| 2025-08-08 | main | Wells Fargo | Equal-Weight → Equal-Weight | $14 |
| 2025-07-18 | main | Craig-Hallum | Buy → Buy | $26 |
| 2025-05-05 | reit | Stephens & Co. | Overweight → Overweight | $40 |
| 2025-05-05 | reit | HC Wainwright & Co. | Neutral → Neutral | $25 |
| 2025-04-17 | main | Goldman Sachs | Buy → Buy | $26 |
| 2025-03-03 | main | HC Wainwright & Co. | Neutral → Neutral | $25 |
| 2025-02-27 | reit | Stephens & Co. | Overweight → Overweight | $40 |
| 2025-01-15 | up | Wells Fargo | Underweight → Equal-Weight | $24 |
| 2025-01-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $26 |
| 2024-11-05 | main | BTIG | Buy → Buy | $35 |
| 2024-10-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-10-16 | main | Goldman Sachs | Buy → Buy | $35 |
| 2024-08-27 | init | Wells Fargo | — → Underweight | $28 |
- CareDx (NASDAQ: CDNA) CFO & COO granted 24,134 RSUs in equity award - Stock Titan Wed, 22 Apr 2026 20
- CDNA (CareDx Inc.) posts 50.8 percent Q4 2025 EPS miss, shares dip 0.34 percent in today’s trading. - UBND thành phố Hải Phòng Wed, 22 Apr 2026 19
- Assessing CareDx (CDNA) Valuation After Recent Share Price Momentum And Mixed Long Term Returns - Yahoo Finance Mon, 20 Apr 2026 02
- CareDx (CDNA) to Sell Lab Products Division to EuroBio Scientifi - GuruFocus Mon, 20 Apr 2026 20
- Stocks to watch after market on Wednesday: CDNA, JBHT, SLG, QDEL - MSN ue, 21 Apr 2026 07
- CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results - Seeking Alpha Sat, 18 Apr 2026 12
- CareDx CEO John Hanna Jr. sells $217,155 in company stock - Investing.com Mon, 20 Apr 2026 21
- CareDx, Inc. (CDNA) Stock Analysis: Exploring Growth Potential And Analyst Consensus - DirectorsTalk Interviews Fri, 17 Apr 2026 09
- CareDx (CDNA) CEO sells 10,282 shares at $21.12 under Rule 10b5-1 plan - Stock Titan Mon, 20 Apr 2026 20
- CareDx (CDNA) Launches Innovative AlloSeq Nano Genotyping Soluti - GuruFocus Mon, 20 Apr 2026 18
- CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA Typing - Yahoo Finance ue, 21 Apr 2026 15
- CareDx data from 95 centers points to earlier heart rejection signals - Stock Titan ue, 21 Apr 2026 20
- How The CareDx (CDNA) Story Is Shifting With CMS LCD Uncertainty And New Guidance - Yahoo Finance Mon, 16 Mar 2026 07
- New CareDx test delivers HLA and blood typing in under 3 hours - Stock Titan Mon, 20 Apr 2026 11
- All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy - Yahoo Finance Fri, 17 Apr 2026 16
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
379.81
+13.79%
|
333.79
+19.07%
|
280.32
-12.89%
|
321.79
|
| Operating Revenue |
|
379.81
+13.79%
|
333.79
+19.07%
|
280.32
-12.89%
|
321.79
|
| Cost Of Revenue |
|
123.24
+12.35%
|
109.70
+7.48%
|
102.07
-9.04%
|
112.21
|
| Reconciled Cost Of Revenue |
|
123.24
+12.35%
|
109.70
+7.48%
|
102.07
-9.04%
|
112.21
|
| Gross Profit |
|
256.57
+14.49%
|
224.09
+25.71%
|
178.26
-14.95%
|
209.58
|
| Operating Expense |
|
281.64
+0.72%
|
279.62
-2.00%
|
285.32
-0.52%
|
286.81
|
| Research And Development |
|
71.43
-1.49%
|
72.51
-12.02%
|
82.42
-8.81%
|
90.39
|
| Selling General And Administration |
|
210.21
+1.49%
|
207.11
+2.08%
|
202.90
+3.30%
|
196.42
|
| Selling And Marketing Expense |
|
102.64
+25.21%
|
81.97
-2.48%
|
84.06
-12.46%
|
96.03
|
| General And Administrative Expense |
|
107.56
-14.04%
|
125.14
+5.30%
|
118.84
+18.37%
|
100.40
|
| Other Gand A |
|
107.56
-14.04%
|
125.14
+5.30%
|
118.84
+18.37%
|
100.40
|
| Total Expenses |
|
404.88
+4.00%
|
389.32
+0.50%
|
387.39
-2.92%
|
399.02
|
| Operating Income |
|
-25.07
+54.86%
|
-55.53
+48.13%
|
-107.06
-38.63%
|
-77.23
|
| Total Operating Income As Reported |
|
-30.78
-175.51%
|
40.77
+120.05%
|
-203.36
-163.32%
|
-77.23
|
| EBITDA |
|
-4.66
+86.99%
|
-35.78
+58.99%
|
-87.24
-42.49%
|
-61.22
|
| Normalized EBITDA |
|
1.05
+100.80%
|
-132.08
-1557.65%
|
9.06
+114.77%
|
-61.33
|
| Reconciled Depreciation |
|
20.42
+3.34%
|
19.76
-0.34%
|
19.82
+23.85%
|
16.01
|
| EBIT |
|
-25.07
+54.86%
|
-55.53
+48.13%
|
-107.06
-38.63%
|
-77.23
|
| Total Unusual Items |
|
-5.71
-105.93%
|
96.30
+200.00%
|
-96.30
-90100.00%
|
0.11
|
| Total Unusual Items Excluding Goodwill |
|
-5.71
-105.93%
|
96.30
+200.00%
|
-96.30
-90100.00%
|
0.11
|
| Special Income Charges |
|
-5.71
-105.93%
|
96.30
+200.00%
|
-96.30
|
0.00
|
| Other Special Charges |
|
5.71
+105.93%
|
-96.30
-200.00%
|
96.30
|
—
|
| Restructuring And Mergern Acquisition |
|
—
|
1.78
-23.15%
|
2.32
|
0.00
|
| Net Income |
|
-21.35
-140.64%
|
52.55
+127.62%
|
-190.28
-148.37%
|
-76.61
|
| Pretax Income |
|
-21.08
-139.89%
|
52.86
+127.80%
|
-190.14
-149.42%
|
-76.23
|
| Net Non Operating Interest Income Expense |
|
9.17
-22.02%
|
11.77
-0.86%
|
11.87
+215.44%
|
3.76
|
| Net Interest Income |
|
9.17
-22.02%
|
11.77
-0.86%
|
11.87
+215.44%
|
3.76
|
| Interest Income Non Operating |
|
9.17
-22.02%
|
11.77
-0.86%
|
11.87
+215.44%
|
3.76
|
| Interest Income |
|
9.17
-22.02%
|
11.77
-0.86%
|
11.87
+215.44%
|
3.76
|
| Other Income Expense |
|
-5.19
-105.37%
|
96.63
+201.77%
|
-94.95
-3333.89%
|
-2.77
|
| Other Non Operating Income Expenses |
|
0.52
+59.27%
|
0.33
-75.68%
|
1.35
+147.11%
|
-2.87
|
| Gain On Sale Of Security |
|
—
|
—
|
0.01
-90.65%
|
0.11
|
| Tax Provision |
|
0.27
-12.58%
|
0.31
+119.86%
|
0.14
-62.80%
|
0.38
|
| Tax Rate For Calcs |
|
0.00
+3400.00%
|
0.00
-97.14%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-1.20
-307.53%
|
0.58
+102.86%
|
-20.22
-90100.00%
|
0.02
|
| Net Income Including Noncontrolling Interests |
|
-21.35
-140.64%
|
52.55
+127.62%
|
-190.28
-148.37%
|
-76.61
|
| Net Income From Continuing Operation Net Minority Interest |
|
-21.35
-140.64%
|
52.55
+127.62%
|
-190.28
-148.37%
|
-76.61
|
| Net Income From Continuing And Discontinued Operation |
|
-21.35
-140.64%
|
52.55
+127.62%
|
-190.28
-148.37%
|
-76.61
|
| Net Income Continuous Operations |
|
-21.35
-140.64%
|
52.55
+127.62%
|
-190.28
-148.37%
|
-76.61
|
| Normalized Income |
|
-16.84
+60.99%
|
-43.17
+62.20%
|
-114.21
-48.91%
|
-76.70
|
| Net Income Common Stockholders |
|
-21.35
-140.64%
|
52.55
+127.62%
|
-190.28
-148.37%
|
-76.61
|
| Diluted EPS |
|
—
|
0.93
+126.27%
|
-3.54
-145.83%
|
-1.44
|
| Basic EPS |
|
—
|
1.00
+128.25%
|
-3.54
-145.83%
|
-1.44
|
| Basic Average Shares |
|
—
|
52.77
-1.84%
|
53.76
+0.83%
|
53.32
|
| Diluted Average Shares |
|
—
|
56.62
+5.31%
|
53.76
+0.83%
|
53.32
|
| Diluted NI Availto Com Stockholders |
|
-21.35
-140.64%
|
52.55
+127.62%
|
-190.28
-148.37%
|
-76.61
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
413.23
-15.85%
|
491.05
+5.19%
|
466.83
-14.03%
|
542.99
|
| Current Assets |
|
257.13
-26.92%
|
351.83
+12.15%
|
313.71
-19.11%
|
387.85
|
| Cash Cash Equivalents And Short Term Investments |
|
177.21
-32.01%
|
260.65
+10.72%
|
235.42
-19.68%
|
293.09
|
| Cash And Cash Equivalents |
|
65.43
-42.95%
|
114.69
+39.53%
|
82.20
-8.59%
|
89.92
|
| Other Short Term Investments |
|
111.78
-23.42%
|
145.96
-4.74%
|
153.22
-24.58%
|
203.17
|
| Receivables |
|
42.63
-34.02%
|
64.61
+26.53%
|
51.06
-23.00%
|
66.31
|
| Accounts Receivable |
|
42.63
-34.02%
|
64.61
+26.53%
|
51.06
-23.00%
|
66.31
|
| Inventory |
|
26.70
+36.93%
|
19.50
+0.16%
|
19.47
+1.24%
|
19.23
|
| Raw Materials |
|
13.16
+20.84%
|
10.89
+2.53%
|
10.62
-11.22%
|
11.96
|
| Work In Process |
|
3.74
-1.40%
|
3.79
-26.93%
|
5.19
+20.55%
|
4.31
|
| Finished Goods |
|
9.80
+103.44%
|
4.82
+31.74%
|
3.66
+23.50%
|
2.96
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
10.59
+49.78%
|
7.07
-8.91%
|
7.76
-15.77%
|
9.22
|
| Total Non Current Assets |
|
156.10
+12.12%
|
139.22
-9.07%
|
153.11
-1.31%
|
155.14
|
| Net PPE |
|
55.73
-3.73%
|
57.89
-11.12%
|
65.14
-7.24%
|
70.22
|
| Gross PPE |
|
94.58
-0.27%
|
94.83
-2.63%
|
97.40
+2.91%
|
94.64
|
| Accumulated Depreciation |
|
-38.85
-5.17%
|
-36.94
-14.50%
|
-32.26
-32.10%
|
-24.42
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
45.37
+12.16%
|
40.45
-1.20%
|
40.94
+17.23%
|
34.92
|
| Construction In Progress |
|
8.28
-30.64%
|
11.94
+43.72%
|
8.31
+8.73%
|
7.64
|
| Other Properties |
|
22.76
-6.49%
|
24.34
-18.57%
|
29.89
-13.83%
|
34.69
|
| Leases |
|
18.17
+0.36%
|
18.11
-0.84%
|
18.26
+5.00%
|
17.39
|
| Goodwill And Other Intangible Assets |
|
72.30
-7.93%
|
78.52
-8.74%
|
86.04
+6.78%
|
80.57
|
| Goodwill |
|
40.34
+0.00%
|
40.34
+0.00%
|
40.34
+7.50%
|
37.52
|
| Other Intangible Assets |
|
31.96
-16.30%
|
38.18
-16.45%
|
45.70
+6.16%
|
43.05
|
| Investments And Advances |
|
24.16
|
0.00
|
—
|
—
|
| Other Investments |
|
24.16
|
0.00
|
—
|
—
|
| Other Non Current Assets |
|
3.90
+39.13%
|
2.81
+44.71%
|
1.94
-55.43%
|
4.35
|
| Total Liabilities Net Minority Interest |
|
110.13
-2.21%
|
112.62
-45.20%
|
205.50
+83.35%
|
112.08
|
| Current Liabilities |
|
89.85
+0.53%
|
89.37
+14.47%
|
78.07
+2.76%
|
75.97
|
| Payables And Accrued Expenses |
|
37.07
-7.52%
|
40.09
-2.55%
|
41.14
-5.94%
|
43.74
|
| Payables |
|
9.99
+29.95%
|
7.69
-40.29%
|
12.87
+29.47%
|
9.94
|
| Accounts Payable |
|
9.99
+29.95%
|
7.69
-40.29%
|
12.87
+29.47%
|
9.94
|
| Current Accrued Expenses |
|
27.09
-16.40%
|
32.40
+14.63%
|
28.27
-16.36%
|
33.80
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
38.11
-0.59%
|
38.33
+94.55%
|
19.70
+16.57%
|
16.90
|
| Current Debt And Capital Lease Obligation |
|
6.51
+6.75%
|
6.10
+2.69%
|
5.94
+6.30%
|
5.59
|
| Current Capital Lease Obligation |
|
6.51
+6.75%
|
6.10
+2.69%
|
5.94
+6.30%
|
5.59
|
| Current Deferred Liabilities |
|
4.65
-4.02%
|
4.85
-14.47%
|
5.67
-23.45%
|
7.40
|
| Current Deferred Revenue |
|
4.65
-4.02%
|
4.85
+2.11%
|
4.75
-11.12%
|
5.34
|
| Other Current Liabilities |
|
—
|
2.54
-54.80%
|
5.62
+140.07%
|
2.34
|
| Total Non Current Liabilities Net Minority Interest |
|
20.28
-12.77%
|
23.25
-81.76%
|
127.43
+252.93%
|
36.10
|
| Long Term Debt And Capital Lease Obligation |
|
19.68
-11.61%
|
22.26
-21.27%
|
28.28
-15.35%
|
33.41
|
| Long Term Capital Lease Obligation |
|
19.68
-11.61%
|
22.26
-21.27%
|
28.28
-15.35%
|
33.41
|
| Non Current Deferred Liabilities |
|
0.18
+10.37%
|
0.16
+20.59%
|
0.14
-94.38%
|
2.42
|
| Non Current Deferred Taxes Liabilities |
|
0.18
+10.37%
|
0.16
+20.59%
|
0.14
|
0.00
|
| Other Non Current Liabilities |
|
0.42
-48.96%
|
0.82
-99.17%
|
99.01
+39663.86%
|
0.25
|
| Stockholders Equity |
|
303.10
-19.91%
|
378.43
+44.81%
|
261.33
-39.35%
|
430.91
|
| Common Stock Equity |
|
303.10
-19.91%
|
378.43
+44.81%
|
261.33
-39.35%
|
430.91
|
| Capital Stock |
|
0.05
-1.96%
|
0.05
+4.08%
|
0.05
-5.77%
|
0.05
|
| Common Stock |
|
0.05
-1.96%
|
0.05
+4.08%
|
0.05
-5.77%
|
0.05
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
50.92
-7.04%
|
54.77
+6.34%
|
51.50
-3.79%
|
53.53
|
| Ordinary Shares Number |
|
50.92
-7.04%
|
54.77
+6.34%
|
51.50
-3.79%
|
53.53
|
| Additional Paid In Capital |
|
1,043.92
+3.03%
|
1,013.19
+7.05%
|
946.51
+5.31%
|
898.81
|
| Retained Earnings |
|
-735.36
-17.42%
|
-626.24
+7.67%
|
-678.27
-47.31%
|
-460.44
|
| Gains Losses Not Affecting Retained Earnings |
|
-5.51
+35.64%
|
-8.57
-23.06%
|
-6.96
+7.20%
|
-7.50
|
| Other Equity Adjustments |
|
-5.51
+35.64%
|
-8.57
-23.06%
|
-6.96
+7.20%
|
-7.50
|
| Total Equity Gross Minority Interest |
|
303.10
-19.91%
|
378.43
+44.81%
|
261.33
-39.35%
|
430.91
|
| Total Capitalization |
|
303.10
-19.91%
|
378.43
+44.81%
|
261.33
-39.35%
|
430.91
|
| Working Capital |
|
167.28
-36.26%
|
262.46
+11.38%
|
235.64
-24.44%
|
311.87
|
| Invested Capital |
|
303.10
-19.91%
|
378.43
+44.81%
|
261.33
-39.35%
|
430.91
|
| Total Debt |
|
26.19
-7.66%
|
28.37
-17.11%
|
34.22
-12.25%
|
39.00
|
| Capital Lease Obligations |
|
26.19
-7.66%
|
28.37
-17.11%
|
34.22
-12.25%
|
39.00
|
| Net Tangible Assets |
|
230.81
-23.04%
|
299.91
+71.09%
|
175.29
-49.97%
|
350.34
|
| Tangible Book Value |
|
230.81
-23.04%
|
299.91
+71.09%
|
175.29
-49.97%
|
350.34
|
| Current Provisions |
|
3.50
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
42.03
+10.47%
|
38.05
+306.92%
|
-18.39
+27.14%
|
-25.24
|
| Cash Flow From Continuing Operating Activities |
|
42.03
+10.47%
|
38.05
+306.92%
|
-18.39
+27.14%
|
-25.24
|
| Net Income From Continuing Operations |
|
-21.35
-140.64%
|
52.55
+127.62%
|
-190.28
-148.37%
|
-76.61
|
| Depreciation Amortization Depletion |
|
20.42
+3.34%
|
19.76
-0.34%
|
19.82
+23.85%
|
16.01
|
| Depreciation |
|
20.42
+3.34%
|
19.76
-0.34%
|
19.82
+23.85%
|
16.01
|
| Depreciation And Amortization |
|
20.42
+3.34%
|
19.76
-0.34%
|
19.82
+23.85%
|
16.01
|
| Other Non Cash Items |
|
0.70
-24.49%
|
0.93
+63.91%
|
0.57
-21.87%
|
0.73
|
| Stock Based Compensation |
|
34.86
-47.50%
|
66.41
+35.29%
|
49.09
+5.44%
|
46.55
|
| Asset Impairment Charge |
|
2.26
|
0.00
-100.00%
|
1.00
+19.05%
|
0.84
|
| Deferred Tax |
|
0.02
+109.09%
|
-0.19
-133.04%
|
0.57
|
—
|
| Deferred Income Tax |
|
0.02
+109.09%
|
-0.19
-133.04%
|
0.57
|
—
|
| Operating Gains Losses |
|
0.05
-47.25%
|
0.09
+136.40%
|
-0.25
-133.64%
|
-0.11
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.29
-174.77%
|
-0.11
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
0.00
|
0.00
-100.00%
|
1.18
|
| Change In Working Capital |
|
3.81
+103.73%
|
-102.12
-196.31%
|
106.03
+845.79%
|
-14.22
|
| Change In Receivables |
|
22.52
+263.90%
|
-13.74
-185.80%
|
16.02
+340.48%
|
-6.66
|
| Changes In Account Receivables |
|
22.52
+263.90%
|
-13.74
-185.80%
|
16.02
+340.48%
|
-6.66
|
| Change In Inventory |
|
-4.96
-387.13%
|
-1.02
-1985.19%
|
0.05
+101.89%
|
-2.86
|
| Change In Prepaid Assets |
|
-4.41
-828.22%
|
0.61
-65.70%
|
1.77
+268.45%
|
-1.05
|
| Change In Payables And Accrued Expense |
|
-3.35
+95.93%
|
-82.10
-187.71%
|
93.61
+425400.00%
|
0.02
|
| Change In Accrued Expense |
|
-4.15
+94.61%
|
-76.99
-184.88%
|
90.71
+4269.27%
|
2.08
|
| Change In Payable |
|
0.81
+115.81%
|
-5.11
-275.96%
|
2.90
+241.38%
|
-2.05
|
| Change In Account Payable |
|
0.81
+115.81%
|
-5.11
-275.96%
|
2.90
+241.38%
|
-2.05
|
| Change In Other Working Capital |
|
—
|
-0.19
-133.04%
|
0.57
+363.26%
|
-0.21
|
| Change In Other Current Liabilities |
|
-6.00
-2.29%
|
-5.86
-8.21%
|
-5.42
-56.77%
|
-3.46
|
| Investing Cash Flow |
|
2.16
+546.79%
|
-0.48
-101.19%
|
40.45
+117.70%
|
-228.50
|
| Cash Flow From Continuing Investing Activities |
|
2.16
+546.79%
|
-0.48
-101.19%
|
40.45
+117.70%
|
-228.50
|
| Capital Expenditure |
|
-6.59
-1.60%
|
-6.48
+29.83%
|
-9.24
+62.03%
|
-24.33
|
| Capital Expenditure Reported |
|
-5.91
+8.81%
|
-6.48
+22.29%
|
-8.34
+60.70%
|
-21.23
|
| Net Investment Purchase And Sale |
|
8.75
+45.74%
|
6.00
-89.35%
|
56.37
+127.69%
|
-203.56
|
| Purchase Of Investment |
|
-145.93
+9.32%
|
-160.92
+20.39%
|
-202.13
+35.86%
|
-315.14
|
| Sale Of Investment |
|
154.67
-7.34%
|
166.92
-35.43%
|
258.50
+131.66%
|
111.59
|
| Net Business Purchase And Sale |
|
0.00
|
0.00
+100.00%
|
-6.68
-995.41%
|
-0.61
|
| Purchase Of Business |
|
0.00
|
0.00
+100.00%
|
-6.68
-995.41%
|
-0.61
|
| Net Intangibles Purchase And Sale |
|
-0.68
|
0.00
+100.00%
|
-0.90
+71.10%
|
-3.10
|
| Purchase Of Intangibles |
|
-0.68
|
0.00
+100.00%
|
-0.90
+71.10%
|
-3.10
|
| Financing Cash Flow |
|
-93.39
-1565.97%
|
-5.61
+81.06%
|
-29.61
-552.83%
|
-4.54
|
| Cash Flow From Continuing Financing Activities |
|
-93.39
-1565.97%
|
-5.61
+81.06%
|
-29.61
-552.83%
|
-4.54
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
-87.77
-16713.79%
|
-0.52
+98.10%
|
-27.54
-4189.88%
|
-0.64
|
| Common Stock Payments |
|
-87.77
-16713.79%
|
-0.52
+98.10%
|
-27.54
-4189.88%
|
-0.64
|
| Repurchase Of Capital Stock |
|
-87.77
-16713.79%
|
-0.52
+98.10%
|
-27.54
-4189.88%
|
-0.64
|
| Proceeds From Stock Option Exercised |
|
8.00
-22.63%
|
10.33
+538.23%
|
1.62
-65.29%
|
4.67
|
| Net Other Financing Charges |
|
-13.62
+11.65%
|
-15.42
-318.49%
|
-3.68
+56.95%
|
-8.56
|
| Changes In Cash |
|
-49.20
-253.96%
|
31.96
+523.41%
|
-7.55
+97.08%
|
-258.28
|
| Effect Of Exchange Rate Changes |
|
-0.09
-116.92%
|
0.53
+575.00%
|
-0.11
-586.96%
|
0.02
|
| Beginning Cash Position |
|
115.27
+39.25%
|
82.78
-8.47%
|
90.44
-74.06%
|
348.70
|
| End Cash Position |
|
65.98
-42.76%
|
115.27
+39.25%
|
82.78
-8.47%
|
90.44
|
| Free Cash Flow |
|
35.44
+12.29%
|
31.56
+214.25%
|
-27.63
+44.27%
|
-49.57
|
| Interest Paid Supplemental Data |
|
—
|
0.00
|
0.00
-100.00%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
0.28
-10.41%
|
0.32
-57.05%
|
0.74
+88.27%
|
0.39
|
| Amortization Of Securities |
|
1.27
+104.99%
|
0.62
+112.60%
|
-4.93
-1363.33%
|
0.39
|
| Common Stock Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
—
|
—
|
0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-22 View
- 42026-04-20 View
- 42026-04-16 View
- 8-K2026-04-16 View
- 42026-04-07 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-01 View
- 10-K2026-02-25 View
- 8-K2026-02-24 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-01-23 View
- 42026-01-20 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|